Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
PR Newswire•28/10/2026•06:45 ET
11
Key Highlights
- ➤Retatrutide cut A1C 2.2% versus Ozempic 2 mg’s 1.8% at 80 weeks
- ➤Retatrutide 12 mg produced 47.4-pound weight loss versus Ozempic’s 20.9 pounds
- ➤Retatrutide met primary and all key secondary endpoints in Phase 3 trial
- ➤Retatrutide improved non-HDL cholesterol, triglycerides and systolic blood pressure versus Ozempic
- ➤TRANSCEND-T2D-2 became retatrutide’s sixth Phase 3 trial showing efficacy
Expert Statements
Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health
“Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today. In TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest approved dose of Ozempic for type 2 diabetes. Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial PR Newswire
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks
Get started
Create a free account to read the full story.